The post Global liquidity hits ATH at $130T – Is 2026 the payoff for risk assets? appeared on BitcoinEthereumNews.com. Heading into 2026, liquidity signals are The post Global liquidity hits ATH at $130T – Is 2026 the payoff for risk assets? appeared on BitcoinEthereumNews.com. Heading into 2026, liquidity signals are

Global liquidity hits ATH at $130T – Is 2026 the payoff for risk assets?

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Heading into 2026, liquidity signals are starting to lean bullish. 

Beyond the three consecutive rate cuts in the second half of the year that marked the start of the easing cycle, the broader liquidity backdrop continues to improve, putting a supportive tailwind behind risk assets.

From a macro perspective, when global liquidity metrics like Global M2 start trending higher, risk assets often follow as investors move further out on the risk curve. Notably, a similar pattern appears to be emerging now.

Source: Alphractal

According to Alphactral data, Global M2 Supply has reached new all-time highs, now approaching $130 trillion.

At the same time, this expansion has been uneven across regions, with China emerging as the primary driver.

Data showed China accounting for roughly 37% of the total, with M2 standing at USD 47.7 trillion. However, several other economies are experiencing M2 contraction, including Japan, India, Argentina, Israel, and South Korea.

Against this setup, the U.S. government’s $40 billion Treasury plan doesn’t look like a one-off.

Instead, major economies appear to be competing on liquidity provision, setting the stage for risk assets heading into 2026.

Liquidity is building, but risk assets stay cautious

Across the globe, liquidity easing seems to be moving in sync.

In the U.S., the $40 billion Treasury plan is designed to inject cash into the banking system by issuing government debt. In turn, this move helps keep funding conditions smooth, indirectly providing a tailwind for risk assets.

Combined with Global M2 hitting ATH and the Fed easing through rate cuts and Treasury measures, the macro setup is clearly favoring risk assets. That said, how much upside we see will depend on investor appetite.

Source: TradingView (TOTAL)

Notably, the macro tailwinds haven’t yet supported gains in this space.

Despite three rate cuts, the TOTAL crypto market cap is down 21% for the quarter, ending 2025 on a bearish note. As a result, risk assets remain well below late-Q3 peaks, keeping investors cautious heading into 2026.

Against this backdrop, the impact of liquidity growth on risk assets isn’t easy to predict. That said, with global money supply rising, it could set the stage for a rebound, making it a key metric to watch in the months ahead.


Final Thoughts

  • Global M2 hits a record, led by China, while major economies ease funding conditions through rate cuts and Treasury measures.
  • Despite easing, crypto is down 21% for Q4 2025, keeping investors cautious, but liquidity trends could set the stage for a rebound in 2026.

Next: Why THIS altcoin pain could be the setup for a 2026 breakout

Source: https://ambcrypto.com/global-liquidity-hits-ath-at-130t-is-2026-the-payoff-for-risk-assets/

Market Opportunity
Aethir Logo
Aethir Price(ATH)
$0.006047
$0.006047$0.006047
-7.22%
USD
Aethir (ATH) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09